PubMed ID:
34277971
Public Release Type:
Journal
Publication Year: 2021
DOI:
https://doi.org/10.1002/edm2.247
Authors:
Wang Katherine M., Li JingWei, Bhalla Vivek, Jardine Meg J., Neal Bruce, de Zeeuw Dick, Fulcher Greg, Perkovic Vlado, Mahaffey Kenneth W., Chang Tara I.
Request IDs:
20629
Studies:
African American Study of Kidney Disease and Hypertension Cohort Study
Patients with type 2 diabetes (T2D) are predisposed to derangements in serum Magnesium (Mg), which may have implications for cardiometabolic events and outcomes. In clinical trials, participants with T2D randomized to sodium‐glucose co‐transporter 2 (SGLT2) inhibitors have shown mild to moderate increases in serum Mg from baseline levels. This post hoc analysis assesses the relation between serum Mg with cardiovascular outcomes in 10,140 participants of the Canagliflozin Cardiovascular Assessment Study (CANVAS) Program.